{
}
UBS analyst Trung Huynh has reaffirmed a Buy rating on Merck (NYSE: MRK) with a price target of $105.00. The analyst noted positive sentiment surrounding the company, indicating confidence in its future performance.
UBS has lowered its price target for Cabaletta Bio Inc. to $7 from $10 while maintaining a Buy rating, following the company's fourth quarter 2024 earnings report. Despite a significant stock decline of over 90% in the past year, analysts remain optimistic, with targets ranging from $3 to $28. The recent report of a Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS) case in a clinical trial has raised safety concerns, but the trial will continue as the event was linked to a protocol deviation. Cabaletta Bio has implemented new precautions to mitigate future risks, and enrollment in its RESET trials has accelerated, with 21 patients now participating.
UBS has lowered its price target for Cabaletta Bio to $7 from $10 while maintaining a Buy rating, following the company's fourth-quarter report that met expectations. Despite a significant stock decline of over 90% in the past year, analysts remain optimistic, with targets ranging from $3 to $28. The recent emergence of a grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS) case has raised safety concerns, but the Independent Data Monitoring Committee recommended continuing the study. Cabaletta has implemented new precautions to mitigate risks, while enrollment in clinical trials is accelerating, potentially enhancing data availability by November.
UBS has maintained a Neutral rating on Eli Lilly (NYSE: LLY) with a price target of $1,100, noting a recent uptick in prescriptions for Zepbound despite previous product performance setbacks. The company has seen a 32% revenue growth over the past year, with expectations for Zepbound adjusted upward by 2%. Looking ahead, the anticipated release of orfo diabetes data in Q2 2025 could significantly boost investor interest, with a 70% probability of success for the ACHIEVE-1 study.
UBS has maintained a "Neutral" rating on Eli Lilly (NYSE: LLY) with a price target of $1,100, noting the company's strong revenue growth despite recent product performance setbacks. The upcoming release of Orfo diabetes data in Q2 2025 is highly anticipated, with a 70% probability of success for the ACHIEVE-1 trial, which could enhance investor interest. Eli Lilly's recent launch of Mounjaro in India positions it competitively in a market facing rising obesity and diabetes rates.
UBS analyst Trung Huynh has reaffirmed a Buy rating on Eli Lilly (NYSE: LLY) with a price target of $1,100. The positive outlook reflects confidence in the company's performance and potential growth in the market.
UBS has maintained a "Neutral" rating for Pfizer, setting a target price of $29. Analyst Trung Huynh noted a solid fourth quarter and highlighted the pharmaceutical company's confirmed outlook for 2025 in a recent study published on February 4, 2025.
UBS analyst Trung Huynh reports that Novo Nordisk's CagriSema Phase 3 obesity data fell short of expectations, achieving a 20.4% average weight loss compared to the anticipated 25%. This outcome is seen as favorable for Eli Lilly and Amgen, reinforcing tirzepatide's leading position and suggesting CagriSema's efficacy aligns more closely with MariTide, which may have gastrointestinal side effects.
UBS analyst Trung Huynh reports that Novo Nordisk's CagriSema Phase 3 obesity data fell short of expectations, achieving a 20.4% average weight loss compared to the anticipated 25%. This outcome is seen as favorable for Eli Lilly and Amgen, reinforcing tirzepatide's leading position in the market. The analysis suggests that CagriSema's efficacy aligns more closely with MariTide, which may present gastrointestinal issues and a less appealing monthly titration regimen.
UBS has maintained a "Neutral" rating for Pfizer, setting a target price of $31. The decision to terminate the lung cancer study with Sasanlimab is attributed to strategic reasons, though high dropout rates raise concerns, particularly regarding the ongoing phase III bladder cancer study.
Trung Huynh
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating and price target for merck
15:45 03.04.2025
ubs lowers cabaletta bio stock target to seven dollars maintains buy rating
16:38 01.04.2025
ubs lowers cabaletta bio price target but maintains buy recommendation
15:52 01.04.2025
ubs maintains neutral rating on eli lilly with 1100 price target
15:33 24.03.2025
ubs maintains neutral rating on eli lilly with price target of 1100
15:26 24.03.2025
UBS maintains buy rating and price target for Eli Lilly
14:03 24.03.2025
ubs maintains neutral rating for pfizer with target price of 29 dollars
17:00 04.02.2025
Eli Lilly and Amgen benefit from Novo Nordisk's disappointing obesity data
13:30 21.12.2024
Novo obesity data boosts outlook for Eli Lilly and Amgen stocks
13:30 21.12.2024
UBS maintains neutral rating on Pfizer amid lung cancer study concerns
08:26 19.12.2024
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Global Trade Developments
Government Economic Policies
Supply Chain Management
Retail and Consumer Goods
Industry Mergers & Acquisitions
Stock Market Updates
Private Equity Deals
Global Financial Events
Venture Capital Investments
CEO Changes
Funding Rounds & Investments
Workplace Trends
Emerging Startups
Finance Mergers & Acquisitions
Energy Sector Developments
Inflation and Monetary Impact
Financial Scams and Security
Countries:
Companies:
Apple Inc.
NVIDIA Corporation
Google Inc.
Samsung Securities Co.,Ltd.
Tesmec S.p.A.
Toyota Motor Corp
Honda Motor Co., Ltd.
Taiwan Semiconductor Manufacturing Company Limited
Microsoft Corporation
International Monetary Fund FUND
Kraken Energy Corp.
Amazon.com, Inc.
JD.com, Inc.
Meituan
KuCoin Token USD
Verizon Communications Inc.
OpenAI ERC USD
The Goldman Sachs Group, Inc.
Dell Technologies Inc.
Nokia Oyj
Currencies:
United States Dollar
Chinese Yuan
Euro
Indian Rupee
Japanese Yen
British Pound Sterling
Indonesian Rupiah
Australian Dollar
New Zealand Dollar
South Korean Won
Offshore Chinese Yuan
Vietnamese Đồng
New Taiwan Dollar
Singapore Dollar
Egyptian Pound
Nigerian Naira
Nicaraguan Córdoba
South African Rand
United Arab Emirates Dirham
Malaysian Ringgit
People:
Donald Trump
Howard Lutnick
Changpeng Zhao
Shigeru Ishiba
Scott Bessent
Chris Wright
Tim Cook
Haider Ali Khan
Justin Sun
Jamieson Greer
Abdulaziz bin Salman Al Saud
Mohammad Al Tamimi
Mohammad Altamimi
Jensen Huang
Sam Altman
Xi Jinping
Christopher Flinos
Mohammed bin Salman Al Saud
Ray Dalio
John Abraham